MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • May 2017

AIVITA Appoints Operations and Customer Care Executive Ed Inal as Chief Operating Officer

AIVITA Biomedical to Feature Skin Care Technology at Upcoming Music City SCALE Symposium

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead Joins Human Immunome Project Board of Directors
  • TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma
  • AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
  • AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.